ARTICLE | Company News
ReNeuron, VistaGen in stem cell deal
June 20, 2001 7:00 AM UTC
ReNeuron (LSE:REN) granted VistaGen (Burlingame, Calif.) an exclusive license to its technology for in vitro toxicity and efficacy screening. VistaGen also received access to REN's neural stem cells, ...